We describe a case of metastatic malignant melanoma with no primary cutaneous lesion presenting as weight loss in a man with refractory, seropositive rheumatoid arthritis (RA). The patient had undergone multiple investigations previously and the case highlights the importance of repeat assessment in elderly patients presenting with unexplained weight loss.
A 76-year-old man with a 17 year history of erosive, seropositive rheumatoid arthritis (RA) was admitted to hospital for investigation of ongoing weight loss. He had been treated with non-steroidal anti-inflammatory agents, low-dose prednisolone and various disease-modifying anti-rheumatic drugs (DMARDs) (penicillamine, sulphasalazine, gold, methotrexate, azathioprine and leflunomide).
He presented with a loss of weight of 9 kg over 9 months associated with anorexia, lethargy, rigors and night sweats. He also complained of polyarthralgia. He consumed 20 units/week of alcohol but had previously drunk approximately 50 units/week for 40 years. He was a non-smoker. Physical examination revealed widespread synovitis and smooth non-tender hepatomegaly. Investigations including CT imaging of his chest and abdomen, bronchoscopy, endoscopy, laparoscopy, bone marrow aspiration and a bone scan had been carried out in the preceding months. None showed any evidence of malignancy or infection.
Results of laboratory studies are shown in Table 1 . Abdominal ultrasound showed hepatomegaly with a diffusely abnormal liver echopattern consisting of multiple, tiny, poorly echogenic nodules. A percutaneous liver biopsy revealed metastatic malignant melanoma. The patient died a number of weeks after the diagnosis was made.
Discussion
The differential diagnosis of this gentleman's weight loss included RA, DMARDs, sepsis and neoplasia. Multiple negative investigations had been performed previously but a repeat assessment of his clinical course and baseline investigations prompted further tests leading to the diagnosis of metastatic malignant melanoma.
Elderly patients with significant unexplained weight loss pose difficult diagnostic and management dilemmas. Significant weight loss is usually a marker of serious disease and even if no disease is found on initial evaluation, patients should be provided with repeat assessments, particularly since occult illness may not become apparent for long periods. Neoplasia is a common cause of unintentional weight loss, accounting for 16-36% of older persons with weight loss, and is the most common occult cause [1] .
Retrospective studies have estimated that only 3% of patients with melanoma present with metastatic disease and no skin lesion, usually with an occult orbital or gastrointestinal primary [2] . Patients with RA are at increased risk of lymphoproliferative disorders and long-term DMARD therapy has oncogenic potential. The annual incidences of malignant melanoma and RA are 10/100,000 and 30/100,000, respectively, such that the presentation of malignant melanoma with RA is rare, with only six cases reported previously [3] [4] [5] [6] .
Melanoma inhibitory activity (MIA) is a protein derived from malignant melanoma cell lines which correlates with metastasis but which is also produced by differentiated chondrocytes. A significant increase in MIA serum concentrations has been shown in patients with seropositive, destructive RA, but no other arthritis, and MIA has been suggested as a serum marker for RA [7] . Malignant melanoma and RA utilise similar matrix degradation enzymes, such as cysteine proteases, and enhanced MIA levels may reflect chondrocyte activation in conjugation with joint destruction in RA.
These observations suggest a potential link between the two pathologies, yet the observation of malignant melanoma and RA in clinical practice is rare. How can this apparent paradox be explained? A potential clue may lie in the observation that immunotherapy with interleukin-2 and interferon-α is now established therapy for metastatic malignant melanoma [8] . These cytokines are elevated in patients with active RA and may precipitate an inflammatory polyarthropathy when administered exogenously in these patients [9] . Perhaps a potential association between RA and malignant melanoma is counterbalanced by the elevated presence of cytokines such as interleukin-2 and interferon-α in patients with RA. This complex association is further enhanced by the observation that the HLA haplotype DRB1*04, which occurs with increased frequency in patients with RA, is an independent favourable prognostic marker in patients with melanoma [10] .
Key points
• Repeat assessments are essential in elderly patients presenting with unexplained weight loss.
• Neoplasia is an important cause of occult unintentional weight loss in the elderly.
• Metastatic malignant melanoma may present in the absence of a primary cutaneous lesion. 
